Mantle Cell Lymphoma | Topics

 
Punctual, Kinetic MRD Analysis May Be MCL Natural History, Progression, and Outcomes Indicator
June 29, 2022

Punctual and kinetic minimal residual disease analysis could be a robust predictor of mantle cell lymphoma’s natural history and could represent an adaptable model for continuous patient risk assessment.

Brexu-Cel Demonstrates Continued Durable Responses at 3-Year Follow-Up in ZUMA-2 Study for Relapsed/Refractory MCL
June 17, 2022

The 3-year follow-up update from the phase 2 ZUMA-2 trial showed continued responses for patients with relapsed/refractory mantle cell lymphoma treated with brexucabtagene autoleucel.

Adding Ibrutinib to Standard-of-Care Significantly Improves PFS in Older Patients with MCL
June 03, 2022

The combination of ibrutinib plus the chemotherapy bendamustine and rituximab immunotherapy elicited the highest PFS rate ever reported for this patient population, according to an expert.

Brexucabtagene Autoleucel May Be a Cost-Effective Treatment for Relapsed/Refractory MCL
May 17, 2022

Treatment with brexucabtagene autoleucel appears to be a cost-effective treatment for patients with relapsed/refractory mantle cell lymphoma following treatment with a Bruton tyrosine kinase inhibitor.

Real-World Early Outcomes With Brexu-Cel in MCL Demonstrate Feasibility and Positive Efficacy
May 04, 2022

Despite its use in a population with broad characteristics and high-risk features, a real-world outcome analysis demonstrated brexucabtagene autoleucel’s feasibility and efficacy in those with mantle cell lymphoma.

Despite PFS Boost, Missing Data About Second-Generation BTKi for R/R MCL May Cause Opportunity Cost
April 27, 2022

Investigators highlight key findings from an early cost analysis of phase 1/2 trials examining Burton tyrosine kinase inhibitors in patients with relapsed/refractory mantle cell lymphoma.

Updated Efficacy and Safety Data Continue to Support Zanubrutinib Use in Released/Refractory MCL
April 07, 2022

Updated data from a pivotal trial that led to the approval of zanubrutinib for the treatment of patients with relapsed or refractory mantle cell lymphoma appears to highlight persistent benefit.

Real-World Evidence Reinforce Brexu-cel as Salvage Strategy in Mantle Cell Lymphoma
March 21, 2022

Patients with mantle cell lymphoma appeared to benefit from brexucabtagene autoleucel as salvage therapy in the real-world setting.

Frontline Ibrutinib Plus Rituximab Yields Promising Response Rates for Indolent MCL
March 01, 2022

Phase 2 data highlighted a high complete response rate and undetectable minimal residual disease rate in patients with indolent clinical forms of mantle cell lymphoma who received ibrutinib plus rituximab.

Induction Ibrutinib/Rituximab Plus R-HCVAD Yields Positive Frontline Activity in Mantle Cell Lymphoma
February 08, 2022

Research from a 2-part, phase 2 trial found that ibrutinib and rituximab followed by hyper-fractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone produced positive response data and a manageable safety profile for younger patients with mantle cell lymphoma.